Adalimumab for treatment of severe ulcerative sarcoidosis
| Autor: | Dominic J. Wu, Malia B Downing, Anand Rajpara, Develyn Vetos |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Sarcoidosis business.industry Cutaneous Sarcoidosis Necrobiosis Adalimumab Hydroxychloroquine Dermatology General Medicine Middle Aged medicine.disease Severity of Illness Index Skin Diseases Pentoxifylline Prednisone Sulfasalazine Skin Ulcer medicine Humans Female Methotrexate business medicine.drug |
| Zdroj: | Dermatology Online Journal. 27 |
| ISSN: | 1087-2108 |
| DOI: | 10.5070/d327654058 |
| Popis: | Ulcerative sarcoidosis is a rare variant of cutaneous sarcoidosis that may present as ulceration with necrotic yellow plaques on the lower extremities, face, arms, trunk, or genital area. Adalimumab, a human monoclonal anti-TNF antibody, is an emerging treatment for recalcitrant cutaneous sarcoidosis. We describe severe ulcerative sarcoidosis in a 60-year-old woman with chronic ulcerative necrobiosis lipoidica-like plaques on her left arm for over 20 years. Her condition had not responded to previous treatments with hydroxychloroquine, methotrexate, and sulfasalazine. After a four-month course of adalimumab therapy in addition to pentoxifylline and prednisone with taper, the patient had significant improvement in her skin disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|